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Anti-inflammatory specific cytokines and chemokines are elevated in many 
advanced tumors and correlate with poor prognosis. However, the differential 
expression of anti-inflammatory cytokines and chemokines in prostate cancer is not 
known. We investigated the hypotheses that androgen unresponsive DU145 and PC3 
prostate cancer cells and androgen responsive LNCaP prostate cancer cells, 
differentially expressed selected anti-inflammatory and pro-inflammatory cytokines 
and chemokines and that, dendritic cells pulsed with prostate tumor antigens will 
induce mainly pro-inflammatory cytokines and chemokines in T cells using mouse 
models. Our results indicated that anti-inflammatory specific cytokines IL-1 0, IL-4, 
and anti-inflammatory specific chemokine CCL- 17 (TARC) and cognate receptor 
CCR4 are expressed in prostate cancer cell lines. Quantitative real-time PCR (qRT- 
PCR) revealed an almost five-fold increase in chemokine CCL17 and its cognate 
receptor CCR4 mRNA in androgen unresponsive DU145 and PC3 prostate cancer cell 
lines compared to androgen responsive prostate tumor LNCaP. Protein analysis 
indicated significantly increased secretion of anti-inflammatory cytokine IL- 10 by 
DU145 and PC3 compared to LNCaP. Furthermore, pro-inflammatory cytokine IFN-y 
and pro-inflammatory chemokine IP- 10 secretion were significantly less in these 
prostate cancer cells, when compared to immortalized normal prostate epithelial cells. 
Our i'n- vivo analysis revealed that T cells were activated by pulsed dendritic cells 
shown in the increase mRNA expression of pro-inflammatory cytokine IFN-y and pro- 
inflammatory chemokine IP- 10, and cognate receptor CXCR3. However, a 
predominant pro-inflammatory response was not observed as anti-inflammatory 
cytokines and chemokines were also seen. The production of anti-inflammatory 
cytokines and chemokines suggests a possible mechanism for prostate cancer to evade 
host immune responses by negatively modulating immune responses that are 
necessary for destroying cancers cells.. Cytokine and chemokine profiles could be 
used as potential prognostic markers for disease progression. Additionally, an 
effacious vaccine will depend on its ability to inhibit the recruitment of known distinct 
functional anti-inflammatory effector molecules, implicated in prostate cancer 
progression. 
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Prostate cancer is the second leading cause of cancer- related death in men in 
the United States of America. The American Cancer Society, 2007 reported that more 
than 65% of all prostate cancer cases occur in older men and it is most likely due to 
the accumulation of genetic changes over time (Giovannucci and Platz, 2002). There 
is also evidence to suggest that prostate cancer is becoming more prevalent in younger 
men (Elkord, 2007). The chances of survival are increased if early detection by means 
of serum testing for elevated levels of prostate specific antigen (PSA), surgical 
intervention and radiation (Abate-Shen et al., 2000) are done. However, Tjoa et al., 
1999 reported that almost 20% of men succumb to the disease after these conventional 
treatments. This agrees with recent findings (Elkord, 2007) that 35% - 61% of 
patients receiving treatments had residual disease. Even though androgen ablation is 
considered a very effective therapy for advanced prostate cancer progression of the 
disease can continue to the point of becoming androgen unresponsive (Elkord, 2007). 
With this in mind, immunotherapeutic approaches that are based upon the 
premise that the immune system plays a critical role in suppressing tumors (Tjoa et al., 
1998) are becoming increasingly popular in cancer treatments. There is mounting 
experimental evidence to support the notion that elevated levels of T cell mediated 
immune responses, particularly Th 1 -driven anti-prostate cancer antigen specific or 
pro- 
inflammatory responses, are necessary to stymie the effects of prostate cancer by 
eliciting protective immunity against it (Shibuya et al., 2004; Mullins et al., 2004). 
Immune cells involved in T cell mediated immunity are C D ~ +  T helper type-1 cells 
and C D ~ '  T cytotoxic cells. Anti-tumor cell mediated immunity are comprised of pro- 
inflammatory cytokines such as IFN-y, IL-2, IL-12 and chemotactic cytokines or 
chemokines, such as IFN-y inducible protein 10 (IP- 10) and monokine induced by y 
interferon (MIG) (Tannenbaum et al., 1998). Anti-inflammatory cytokines IL-4 and 
IL- 10 and anti-inflammatory chemokines IL-8; GRO-a, CCL 17 (TARC) are known to 
contribute to an immunosuppressive environment (Conticello et a1 2004; Mullins et 
al., 2003; Ishida et al., 2006 and Maccron et al., 2002). Conticello et al., 2004 
reported that in- vivo production of IL-4 supported tumor growth by up regulating 
anti-apoptotic genes such as cFLIP1 Fas-associated death domain-like anti-apoptotic 
molecule (FLAME) 1 and Bcl-xL in breast, bladder, and prostate tumors. McCarron et 
al., 2002 reported that elevated serum IL-10 levels were detected in patients with 
various solid tumors. Elkord, 2007 reported that cancers such as melanoma, ovarian 
carcinoma and B- cell lymphoma produced IL- 10. Additionally, IL- 10 secretion by 
tumors can c0nver.t immature dendritic cells (potent antigen presenting cells) into 
TGF-P and IL-10 secreting T suppressor cells (Ghiringhelli et al., 2005). 
Furthermore, IL-10 may help tumors evade the immune system by interfering with 
IFN-y production and suppressing the expression of chemokines (IP- 10) and MIG 
(Gasperini et al., 1999). 
IP-10 and MIG are ELR- CXC chemokines that play an important role in 
inhibiting angiogenesis (the formation of new blood vessels from pre-existing ones), 
in a tumor model system (Strieter, 2001). IP-10 has also been demonstrated to exert 
anti-proliferative effects in LNCaP prostate tumor cells (Nagpal et al., 2006). 
Frederick et al., 2001 demonstrated that along with MIG, IP-10 was shown to reduce 
the growth of new blood vessels stimulated by either vascular endothelial growth 
factor (VEGF) or angiogenic CXC chemokines such as IL-8 in a rat corneal 
micropocket assay. 
Angiogenesis is important for tumor survival, growth and invasion as well as 
metastasis (Strieter, 2001). Chemokines and their cognate receptors in addition to 
being chemotactic are also implicated in the induction of proteases such as 
metalloproteinases (MMPs) (Payne et al., 2002). Chemokines have the ability to 
direct the trafficking of T lymphocytes and dendritic cells among other immune cells 
to the tumor microenvironment. TARC is known to be produced by tumor cells and 
preferentially attract T suppressor cells and other cells that bear its cognate receptor 
CCR4, to the tumor microenvironment, thus creating a suitable environment for 
survival and growth (Ishida et al., 2006). 
The skewing of Thl-driven pro-inflammatory cytokine and chemokine 
responses to a predominant Th2 driven anti-inflammatory cytokine and chemokine 
response, is therefore necessary for tumor progression. Hence, cytokines, chemokines 
and their cognate receptors may be potential targets for prostate cancer 
immunotherapy. Furthermore, cytokine and chemokine expression profiles can be 
useful as biomarkers for potential disease progression and could be used to identify 
patients who may benefit from immune modulation treatments (Quatan et al., 2006). 
Additionally, identifying and targeting cellular and molecular factors that mediate the 
induction of Thl inducing pro-inflammatory and cytolytic anti-tumor cellular 
responses are of prime importance in the design of effective therapies against prostate 
cancer. Therefore, the intent of this study was to examine the expression profiles of 
anti-inflammatory cytokines; IL-4, IL- 10 and chemokine, TARC and cognate receptor 
CCR4 and, pro-inflammatory cytokine; IFN-y and chemokines, IP-10 and MIG and 
chemokine cognate receptor CXCR3 in prostate cancer cells; DU145, PC3 and 
LNCaP. These selected cytokines and chemokines, have biological importance in 
immunity and cancer progression. In addition, influence of prostate tumor associated 
antigen pulsed dendritic cells on cytokine and chemokine profiles in T lymphocytes 
was investigated. 
We hypothesized that anti-inflammatory and pro-inflammatory cytokines and 
chemokines are differentially expressed in androgen unresponsive DU145 and PC3 
prostate cancer cell lines and androgen responsive LNCaP prostate cancer cell line. 
We also hypothesized that, anti-inflammatory and pro-inflammatory cytokines 
and chemokines expressed by prostate cancer cells will affect the profile of cytokines, 
chemokines and their receptors expressed by T helper and dendritic cells, which would 
influence the presentation of prostate cancer antigens to anti-tumor pro-inflammation 
specific T cells and potentiate a more robust pro-inflammatory response. To test the 
above hypotheses, the following aims were investigated. 
1. To profile anti-inflammatory and pro-inflammatory chemokines and 
cytokines in two androgen unresponsive prostate cancer cell lines, DU145 
and PC3, and androgen responsive LNCaP prostate cancer cell line 
compared to PZ-HPV-7 immortalized normal prostate epithelial cell line 
(I-PrEC). 
2. To profile cytokines and chemokines expressed by T cells when stimulated 
with dendritic cells pulsed with prostate tumor associated antigens from 
DU14.5, PC3, and LNCaP prostate cancer cell lysates. 
By fulfilling these aims, a better understanding and knowledge of the functions 
of cytokines and chemokines in prostate cancer will be gained. 
CHAPTER 2 
REVIEW OF THE LITERATURE 
T Cell Mediated Immunity 
T lymphocytes or T cells are described as groups of small leukocytes that are 
the hallmark of cell-mediated immune responses (Jiang and Chess 2006). The 
regulation of the immune response by T lymphocytes relies on the nature and mode of 
action of these cells. They are responsive to an infinite number of antigens, mainly 
due to the extremely large repertoire of T- cell clones and epitopes (Jiang and Chess, 
2006). 
Immature T cells unlike B cells, which mature within the bone marrow, 
migrate from the bone marrow to the thymus where they become mature by expressing 
receptors for antigens (Jiang and Chess 2006). There are several distinct subsets of T 
lymphocytes. However, significant to this study are the T helper cells, T cytotoxic 
cells and T regulatory cells also known as T suppressor cells. T helper cells are also 
characterized based on their unique glycoprotein cell surface cluster of differentiation 
4 or CD4 (Pitcher et al., 1999). The three primary phenotypes of T helper cells are Th 
0, Thl,  and Th2. Tho or na'ive C D ~ +  expressing T cells recognize only antigens that 
are presented by major histocompatability complex (MHC) class I1 molecules 
presented by antigen presenting cells (APCs) (Ribas et al., 2000). Upon stimulation 
by antigen, na'ive C D ~ + T  cells or Tho cells, differentiate into Thl specific or Th2 
by antigen, nayve C D ~ + T  cells or Tho cells, differentiate into Thl specific or Th2 
specific T cells hence, T helper cell polarization depends on the cytokine milieu and 
antigen presenting cells (Benjamini et al., 2002). 
T cytotoxic or C D ~ '  T cells, are distinct from T helper cells primarily on the basis of 
the expression of the glycoprotein cell surface marker known as cluster of 
differentiation-8 or CD8 (Wong et al., 2003). They are known as the primary 
effectors of the immune system and become activated by antigens presented only by 
MHC class I molecules and cytokines produced by proliferating T helper cells (Ribas 
et al., 2000). C D ~ +  T cells mediate their effector function by releasing IFN-)I and 
tumor necrosis a (TNF-a) or, through a direct cytotoxic mechanism which involves 
the release of the cytolytic protein perforin, which creates pores on the membrane of 
the target cell and the release of Granzyme B, an exogenous serine protease, which 
enters the target cells through the pores created. Granzyme B triggers the activation of 
apoptotic signaling cascade and induces cell death (Ribas et al., 2000). 
A distinct type of lymphocytes called T suppressor or T regulatory 
lymphocytes constitute 1% - 3 % of T lymphocyte cell population in humans and 5% - 
10% in rodents (Ghiringhelli et al., 2005). They are known to suppress antibody 
mediated and cell mediated responses. 
Cytokines: the chemical messengers 
Cytokines are a group of polypeptide molecules and are produced by dendritic 
cells, and are responsible for activating T lymphocytes among other cells of the 
immune system. Cytokines play a crucial role in regulating both humoral and cell- 
mediated immune responses (McCarron et al., 2002). Their mechanism of action can 
be autocrine (exerting effect on cells that produce them) or paracrine (targeting 
neighboring cells), thereby eliciting a signaling cascade by binding to their cognate 
glycoprotein receptors, consequently altering gene transcription and translation 
(Simons et al., 2002). The production of cytokines is one of the signature functions of 
activated C D ~ '  T helper cells. C D ~ '  T cells are important regulators of C D ~ '  T cells, 
B-lymphocytes, and macrophages. 
Cytokine secretion is also important in causing T helper cells to differentiate 
into type 1 and type 2 phenotypes depending on the cytokine milieu and antigen 
presenting cells. The proliferation and differentiation of B-lymphocytes in to antibody 
producing cells are affected by type 2 T helper C D ~ '  cells (Simons et al., 2002). 
Cytokine cascades determine what systems are activated, which are suppressed and 
the duration of activation or suppression (which are usually ephemeral or short-lived) 
(Simons et al., 2002). In other words, they may have synergistic effects; for example, 
IL-12 can up-regulate IL-2 receptors. IL-2 is secreted by type one T helper cells (Thl) 
and act in an autocrine manner to secrete IL-2. Others act antagonistically, 
suppressing the biological functions of certain cytokines; for instance, high levels of 
IL- 12 can inhibit the action of anti-Thl cytokines such as IL- 10 and vice versa. 
Furthermore, high levels of IL-12 are important in the augmentation and maintenance 
of Thl cellular responses by secreting pro-inflammatory cytokines such as IFN-y, IL- 
2, GMCSF, and TNF-a. Cytokine IL-4 also mediates the differentiation of Tho into 
Thl and Th2 cells (Benjamini et al., 2000). High levels of IL-4 contributes to the Th2 
type of immune response and modulates the production of Th2 cytokines IL-5, IL-6, 
IL-8, IL- 10, and IL- 13, and will inhibit Thl development because IL-4 down regulates 
IL-2, an important mediator in Thl mediated proliferation and development (Ghiasi et 
al., 200 I), (Fig. 1). IL-4 and IL- 10 as mentioned in the previous chapter have 
important implications in cancer progression. IL- 10 is a pluripotent Th2 cytokine with 
potent effects on numerous cell populations particularly, circulating and resident 
immune cells, as well as epithelial and some other parenchymal cells (Benjamini et al., 
2002). The biological effects of IL-10 are mediated through cell surface receptors. 
The functional receptor complex of IL-10 consists of at least two subunits, IL-1 OR1 
and IL-1OR2 (Asadullah et al., 2003). Two signaling pathways, the Janus kinase- 
l(JAK1) and the Tyrosine Kinase-2 (TYK2) pathways are said to be associated with 
IL- 10 R l  and IL- 1 OR2 respectively (Dang et al., 2006). It is suggested that by the 
modulation of cell surface IL- 1 OR1, IL- 10 may have immunostimulatory or 
immunosuppressive effects (Ding et al., 2001). Cytokine IL-10 is also known to 
suppress the maturation of dendritic cells (Beckebaum et al., 2004). This effect is 
mainly due to the down-regulation of MHC class I, MHC class 11, and B7 molecules 
(Matsuda et al., 1994; Salazar-Onfray et al., 1999). T suppressor cells, once mature, 
secrete high concentrations of IL-10 and TGF-P proteins (Ghiringhelli et al., 2005). 
The implications of IL-10 is also demonstrated in a one study to show that 
IL- 10 knockout APCs or antisense oligonucleotide treated antigen presenting cells 
(APCs), were more potent activators of the Thl response from nayve or immune cells 
and were effective cellular vaccines against genital chlamydia infection (Igiestme et 
al., 2000). 
The proper balance between anti-inflammatory and pro-inflammatory immune 
response is therefore necessary for averting autoimmunity by and maintaining 
protective immunity. The immunological consequences of deregulation of anti- 
inflammatory and pro-inflammatory responses are therefore important in the context 
of prostate cancer immunotherapy. 
Figure 1. Schematic representation of cytokine production. Antigen 
presenting cells are necessary for the activation of T helper C D ~ +  cells, natural 
killer cells (NK), T killer cells (TK) which secrete, among other cytokines, IL-12 
and IL-4. Tilting the balance between Thl type cytokines and Th2 type cytokines, 
will determine the type of T helper cell phenotype that dominates. (Adapted by 
Scientific Research Enterprise, 2007). 
Chem okines: potent attractors 
Chemokines are a family of small (8 -14kDa) soluble chemo-attractant 
cytokines (Tanaka et al., 2005). To date, four subfamilies of chemokines have been 
characterized (CXC, CC, C and CX3C) based primarily on their cystein motifs 
(Allavena et al., 2005). Binding to their cognate receptors triggers signaling events 
through heterotrimeric seven transmembrane G-protein-coupled receptors (GPCRs) 
(Fredrick et al., 2001). Such signaling cascades may promote cytoskeletal 
rearrangement, the adhesion of tumor cells or leukocytes to endothelial cells as well as 
the directional trafficking and migration of cancer cells (Singh et al., 2004). There is 
reason to believe that chemokines regulate tumor growth in humans and other 
vertebrate species by modulating angiogenesis, activating tumor specific immune 
responses and autocrine growth stimulation (Frederick and Clayman, 2001). In 
humans, there are approximately 50 known chemokines (Frederick et al., 2001) and 18 
known receptors (Tanaka et al., 2005). Chemokine receptors are differentially 
expressed by immune and non-immune cell populations (Fredrick et al., 2001). 
Chemokine receptor expression and association with Thl and Th2 phenotypes are 
affected by other cytokines present during polarization (Sallusto et al., 1998). Thl and 
Th2 lymphocytes differentially express chemokine receptors and migrate in response 
to the different chemokines (Bonecchi et al., 1998). 
As mentioned in the previous chapter, Interferon inducible protein- 10 (IP-10) 
or CXCL10 is known as a potent angiostatic CXC chemokine that is induced by pro- 
inflammatory stimuli in many cell types (Arenberg et al., 1996). It is lOkDa in size 
and lacks a Glu-Leu-Arg amino acid sequence or (ELR motif). In contrast, CXC 
angiogenic chemokines such as IL-8 and Gro-a (Moore et al., 1999), contain the ELR 
motif (Arenberg et al., 1996). IP-10 is a pleiotropic molecule capable of eliciting 
many biological effects, including stimulation of monocytes, natural killer cells, T cell 
migration, bone marrow progenitor maturation, and the modulation of adhesion 
molecule expression (Neville et al., 1997). IP-10 is also known to induce the 
expression of transcription factor and tumor suppressor p53, which is responsible for 
cell cycle arrest and the induction of apoptosis in cancers (Zhang et al., 2005). 
Thymus and activation-regulated chemokine (TARC) or CCL17, is a CC 
chemokine that is expressed constitutively in the thymus (Imai et al., 1997). It 
selectively attracts or directs the trafficking of Th2 lymphocytes and other cells 
bearing its cognate receptor CCR4 especially C D ~ '  ~ ~ 2 5 '  T regulatory cells 
(Ghiringhelli et al., 2005) and mature dendritic cells (Charo et al., 2006). The roles of 
TARC, the endogenous ligand for CCR4, is produced by tumors and the tumor 
microenvironment and as mentioned previously, is responsible for recruiting CCR4 
expressing T suppressor cells to the tumor microenvironment and support its tumor 
growth potential (Ishida et al., 2006). 
Role of Dendritic Cells 
Dendritic cells (DC) are potent antigen presenting cells (Tjoa et al., 1999) and 
induce antigen specific T cell response. They have been used in clinical pilot trials to 
elicit tumor specific immunity as well as clinical response in selected patients with 
success (Nestle, et al., 2000). Dendritic cells (DCs) are known to provide an elaborate 
mechanism for activation of C D ~ +  type one T helper lymphocytes (Igiestme et al., 
2000). Immature DCs actively acquire antigens through macropinocytosis (Sallusto et 
al., 1995). When dendritic cells mature, co-stimulatory proteins CD40, CD 80 (B7. I), 
CD86 (B7.2), MHC class 11, CD54, and intercellular adhesion molecule (ICAM) 
become up regulated which is necessary for binding to T cell receptors and activation 
of naYve T cells (Sattaporn et al., 2001). 
Activation of T cells further augment the biological effect of DCs by secreting 
cytokines and chemokines that modulate their activity (Simons et al., 2002). The Th 1 
cytokine IFN-y stimulate dendritic cells to produce IP- 10 and MIG, which enhance 
them to attract C D ~ '  cells that preferentially express cognate receptor CXCR3 
(Barnes, 2004). However, because most tumors express a small amount of tumor- 
associated antigen that can be cryptic, T cells may not easily recognize them 
(Benjamini et al., 2002). Furthermore, tumor cells tend to lack co-stimulatory 
molecules necessary for proliferation of T cells, cytokines, and activation of tumor 
specific C D ~ + T  lymphocytes (Schott et al., 2006). The effectiveness of tumor 
immunity therefore relies on the presentation of tumor associated antigens by potent 
dendritic cells, the activation of specific T cells, and the homing of tumor associated 
antigens (TAAgs) specific T cells to the tumor site for effective elimination of 
malignant cells (Fig. 2) (Schott, 2006). 
Figure 2. Illustration of role of dendritic cells and their effect in anti-tumor 
immunity (Adapted: Schott, Matthias-Endocrine-Related Cancer, 2006. (A) Immature 
dendritic cells will present tumor associated antigens (TAAs) to T lymphocytes 
without the presence of co-stimulatory molecules; this can lead to T cell anergy. (B) 
Mature DCs will induce immunity. Co-stimulatory molecules are up regulated and 
TAAs are displayed by MHC class I1 to T lymphocytes the paracrine interaction of 
DCs and T lymphocytes leads to further activation and stimulation of cytotoxic T 
lymphocytes, which are important in anti-tumor immunity. 
CHAPTER 3 
MATERIALS AND METHODS 
Prostate Cell Lines and Immortalized Cell Line Procurement: Androgen responsive 
prostate cancer cell LNCaP and androgen unresponsive prostate cancer cell lines DU-145 
and PC3 are human prostate adenocarcinoma cell lines taken from patients inflicted with 
prostate cancer. PC3 was derived prostatic adenocarcinoma metastatic to the bone, 
DU145 was derived from prostatic adenocarcinoma metastatic to the brain, and LNCaP 
was derived from a needle biopsy of the supraclavical lymph node of a patient with 
metastatic prostate adenocarcinoma (Moore, et al., 1999). These prostate cancer cell 
lines were kindly provided by Dr. Jaideep Chaudary, Graduate Student Advisor and Dr. 
Shafiq Khan, Director of the Center for Research and Therapeutic Development, Clark 
Atlanta University. Dr. Nathan Jideama, Clark Atlanta University, kindly provided PZ- 
HPV-7 immortalized normal prostate epithelial cell line. 
Cell Culturing: DU145 and PC3 were maintained in MEM supplemented with 100UIml 
penicillin (Atlanta Biological; Atlanta, GA), 100ug/ml streptomycin and 10% FBS in 
humidified 5% C 0 2  incubator at 37' C. LNCaP and immortalized normal prostate cells 
were cultured in RPMI 1640 medium (Atlanta Biological, Atlanta, GA) supplemented 
with 100UIml penicillin, 100ug/ml streptomycin (Atlanta Biological, Atlanta, GA) and 
10% Fetal Bovine Serum (Atlanta Biological, Atlanta, GA) in humidified 5% C02. Cells 
grown to confluency were trypsinized with 0.25% Trypsin-EDTA and counted using 
Coulter Instrument (Beckman, USA). Culture medium containing 1.5 x lo4 cells lml 
supplemented with 10 % FBS were seeded on 6-well plates and monitored over a 2-day 
period. 
Figure 3: Morphology of Cell lines. Confocal microscopy to 
reveal the morphology of cell lines used in this study. (A) PZ 
HPV-7 immortalized normal prostate epithelial cells; (B) LNCaP, (C) DU14.5; 
and (D) PC3. Magnification X10 
RNA Isolation: Cells grown to confluency were harvested and total RNA was extracted 
using an RNeasy Mini Kit (Qiagen, Valencia, CA) following manufacture's instructions. 
Total RNA was eluded from columns into a final volume of 30 yl in RNase free water 
and stored at -80' C or immediately used for cDNA synthesis. RNA concentration was 
measured with a Gene Quant Pro DNAIRNAI protein calculator, Amersham Biociences 
(Pittsburgh, PA). 
Complementary DNA synthesis (cDNA) : Approximately 0.25 y g of total RNA was 
reverse transcribed using Enhanced Avian HS RT-PCR Kit, Sigma (St Louis, MO). 
Briefly, total RNA was heated at 70° C for 10 minutes with 1y1 oligo (dT) primers at a 
concentration of 3.5 pM. Samples containing a final volume of 10 p1 were cooled on ice 
for two minutes. Ten micro liters of RT-PCR mixture that comprised of PCR water, 2 yl 
lox RT Buffer, 1 pl of RNase inhibitor and 1 pl Enhanced Avian reverse transcriptase, 
were added to each sample to make a final volume of 20 pl. Complementary DNA 
synthesis was performed on samples incubated in a 50" C water bath for 50 minutes. 
Synthesized cDNA was stored at -20' C until needed. 
Qualitative Polymerase Chain Reaction: Polymerase chain reactions (PCR) were 
performed using Enhanced Avian HS RT-PCR Kit, Sigma (St Louis, MO). Each tube 
contained a total volume of 50 pl: 2 pl of cDNA from RT reaction; 1 p1 of dNTP mixture 
(1 00 pM); 5 p1 of 1 Ox Accutaq buffer; 1 pI of Jumpstart Tag polymerase (3.5 pglml); and 
I pI each of (human forward and reverse primers). Primer pairs were designed by 
Integrated DNA technologies SciTools Primer Quest software, Coralville, IA (Tables 1 
and 2). The conditions for DNA amplifications were set as follows: heating at 94" C for 
5 mins, followed by 3.5 cycles of DNA denaturing at 94" C for 2 mins. The annealing 
temperature was set at 65" C for 1 min; with an extension at 72" C for 2 mins, with a final 
extension step at 72" C for 10 min. PCR products were analyzed in 2.5% agarose gel 
containing ethidium bromide under ultraviolet (UV) light. 
Table 1. Primer pairs for selected human cytokine and chemokine genes of interest and 
their product size. 
Genes of Primer Pairs Product 
Interest size bp 
IFN-)I S ~ W  CATCAGGGTCACCI'GACACATTCA 184 
Anti-sew ACI'AGGCAGCCAACCI'MGCAAGA 
IL-4 S e w  TMTGMTGCAGTGCCAATCGGGC 172 
Anti-sew TCAGGAAACAGCCACTTGGGAGAT 
IL-10 Se~TAAATGACI'GcrCGcrGCCTITGC 125 
Anti-sew TGTGGG~CAGCCI'AGATTCCCM 
MIG S e w  TCCI'AAGCCI'GTTAGCATGCTGGT 111 
A n k w  TGTGAGGCCTGTAGGCI'GATTCAA 
TARC S e w  ATCI'CCCI'CACI'GTG(3crCI'CIT 162 
Anti-sew TAATGAATGCAGTGCCAATCGGG 
CXCR3 S e w  TTCI'GTGGTGGTTCI'GGTCCI'GTT 133 
Anti-sew AAGCCCACCAAGTACATCCAGGM 
CCR4 Sense- TTCI'GTGGTGGTTCI'GGTCCI'GTT 192 
Anti-sew AGCCCACCMGTACATCCAGGAAA 
Table 2. Primer pairs for selected mouse cytokine and chemokine genes of interest and 
their product size 
Genes of Primer Pairs Product 
Interest size bp 
IFN-y Sense GTGAlTGGCGGGGTI'GTATCT 117 
Antisem GGGTCACTGCAGCI'CI'GMT 
IL-4 Sense CCAAGGTGCITCGCATATIT 144 
Anli-sense-TGGACI'CAlTCATGGTGCAG 
IL-10 Sen~e- TCCITGGAAAACCTCGTTG 175 
Antisense TCCCCAATGGAAACAGCITA 
TARC Sense CAAGCTCATCTGTGCAGACC 153 
Antisense- CTGGTCACAGGCCGTTITAT 
CCR4 Sense CCTCCCI'ACACMCCTGGM 161 
Antisense GAGGGGTMTGGMGGATGG 
IP-10 S e m  TCCITGTCCTCCCTAGCrCA 127 
Antisense TTGATMCCCCITGGGMGA 
CXCR3 Sense ACGTGGTGGT-AGTGGT 154 
Anti-sense CTCCCACAAGGCATAGAGC 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR): Quantification of 
differences in mRNA expression of IL- 10, IL-4; IFN-y, IP- 10; MIG and cognate receptor 
CXCR3, and CCL17 and cognate receptor CCR4 mRNA expression levels in normal and 
cancer cell lines were determined by real-time-PCR using iCycler Detection System, Bio- 
Rad Laboratory (Hercules, CA). Fluorescent DNA-binding dye iQSYBR Green Super 
mix from Bio-Rad Laboratory was added to standard PCR mixture. Optimum conditions, 
annealing temperature, primer, and template concentrations were pre-determined. 
Briefly, the reaction conditions for real time PCR were the following: 30 cycles 
consisting of 15 s incubation at 95' C and 1 min incubation at 60' C on the I-Cycler IQ, 
Bio-Rad, (Hercules, CA). Quantitative gene expression results were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or Beta Actin before the fold 
change in gene expression was calculated. All standard and qRT-PCR were done in 
triplicates. 
Multiplex Enzyme Linked-Immunosorbent Assay (ELISA): Supernatants from cell 
lysates were analyzed by multiplex ELISA from Quansys Biosciences (Logan, UT), 
according to manufacturer's instructions. 
Statistical Analysis: Two tailed t test were performed using Graphpad to evaluate 
differences between prostate cancer cells and I-PrEC. Analysis of variance (ANOVA) 
was performed using Sigma Stat S statistical software to evaluate differences among 
multiple experimental groups. All statistical analysis was judged at the P<0.05 level of 
significance. Samples were analyzed in triplicates, and reported as the mean standard 
error. 
Protein Determination: LNCaP, PC3, DU- 145 and immortalized normal prostate 
epithelial cells were grown to confluency in 150 cm2 flasks and lysed by freeze thawing. 
Lysates were centrifuged at 3000 rpm at 4' C for 1 hour and supernatant collected and 
stored at -80° C until needed. The protein concentration was determined by Bradford 
assay method according to manufacture's instruction Bio-Rad (Hercules, CA). Each data 
point calculated to represent the mean k SEM of triplicate samples. Calculation of 
protein concentration from Bradford Assay was used to determine the amount of tumor 
lysates to be added to DCs at a cell ratio that range from 1 to 100 DCs for each 500 yg of 
tumor lysate protein (Weiss et al., 2004). 
Animal Procurement, Care and Maintenance of Animal Subjects: Twenty 10- 12 weeks 
old C57BL16J male mice were purchased from The Jackson Laboratory (Bar Harbor, 
MA). The animals were kept in a pathogenic free condition in Laminar flow racks at 12 
hours light and 12 hours darkness and fed with food and water ad  libitum, at the Atlanta 
University Center Animal Care Facility, Morehouse School of Medicine Atlanta, GA. 
Dendritic Cell Isolation: Dendritic cells were harvested from the bone marrow of five 
C57BLl6 male mice. The femoral plugs were forced into cell culture medium (through 
the lumen of the femur) by using a 5 cc syringe with a 23-gauge needle. This procedure 
was repeated until the femur is clear. The cells were refluxed several times to remove 
cell aggregates. The numbers of cells were counted re-suspended in medium containing 
10 nglml of GM-CSF and 5 nglml of IL-4 at a concentration of 3.2 X 1 o6 cells Iml. Ten 
milliliters of suspension were cultured in a flask and incubated for 3 days at 37' C using a 
shaker. Non-adherent cells were collected and discarded. The medium was replaced with 
fresh medium containing GM-CSF and IL-4. After five days, non-adherent cells were 
transferred to culture dishes and incubated for 2 hrs at 37" C. Cells were re-extracted to 
remove possible contaminants, including macrophages. Dendritic cells were pulsed with 
androgen responsive and androgen unresponsive cells at the calculated optimal cell and 
lysate protein concentration of (500 pg Iml) overnight. 
Immunization of C57BL/ 6JMice: Five experimental groups each containing three mice 
of wild type C57BL16J background were immunized subcutaneously with TAA pulsed 
dendritic cells for one week. Group one was pulsed with PC3 tumor lysate. Group two 
were pulsed with DU145 tumor lysate. Group three were pulsed with LNCaP tumor 
lysate. Group four were pulsed with lysates from normal prostate epithelial. Group five 
served as positive control. 
TLymphocyte Isolation: Briefly, the spleen from wild-type mice previously immunized 
intramuscularly with tumor lysates were harvested. T cells were isolated and purified 
using the nylon wool column method. Purified T cells were then co-cultured with UV- 
irradiated splenocytes (used as feeder cells), normal prostate epithelial, PC3 and DU145 
and LNCaP prostate tumor cell lysate at rate of 2x lo5 cells/ml for 5 days at 37" C in a 
5% COz incubator. Supernatants and pellets were collected by centrifugation and stored 
at -80" C until needed. 
CHAPTER 4 
RESULTS 
Pro-inflammatory responses are down regulated prostate cancer cells. 
Qualitative PCR analysis of Thl pro-inflammation specific chemokine IP-10 
(CXCL 10) was observed to be significantly down regulated in prostate cancer cells 
DU145, PC3 and LNCaP (Fig. 5). Furthermore, ELISA measurements for IFN-)I and 
IP-I 0 secretion revealed an almost 10 fold and 5-fold decrease respectively in these 
prostate cancer cells when compared immortalized normal epithelial cells (Fig 6 and 
7). Interestingly, the mitogen PMA caused a significant increase in the chemokine IP- 
10 that is known to have anti-proliferative effects (Nagpal et al., 2006) (Fig. 8). This 
highlights the role of IP-10 in mediating anti-proliferative and angiostatic events in 
cancer cells. Additionally, qualitative PCR analysis showed that there were no 
significant differences in mRNA expression of pro-inflammatory chemokine and 
angiostatic MIG in prostate cancer cell lines DU145, PC3, and LNCaP compared to I- 
PrEC (Fig. 8). MIG may be less important as an antagonist to angiogenic events in 
prostate cancer cells. 
IP-10 down regulation suggests that prostate cancer cells are less likely to 
recruit cytotoxic T cells expressing cognate receptor CXCR3. Moreover, the down 
regulation of IFN-y may enhance the survival and growth in these cancer cells. 
I-PrEC DU145 PC3 LNCaP 
GAPDH 350 bp 
Figure 4. Qualitative analysis of IP-10 mRNA Expression. Shown is 
qualitative analysis of PCR products run on 2.5% agarose gel and visualized 
using ethidium bromide under UV light. Lane 1; PZ-HPV-7 Immortalized 
prostate epithelial cells (I-PrEC): Lane 2; DU145, Lane 3: PC3 and Lane 4: 
LNCaP prostate cancer cell lines. 




Figure 5. IP-10 secretion in prostate cancer cells. Shown are ELISA 
measurements of IP- 10 in prostate cancer cell lines: DU145, PC3 and LNCaP 
compared to I-PrEC (P <0.0001). Data analyzed by Graphpad Software, San 







Figure 6. IFN-y secretion in prostate cancer cells. Shown are ELISA 
measurements of IFN-)I in prostate cancer cell lines: DU145, PC3 and LNCaP 
compared to I-PrEC (P <0.0001). Data analyzed by Graphpad Software, San 
Diego, CA. Standard error bars represent + SEM of triplicate samples. 
Figure 7. Mitogen regulation of chemokine IP-10 in LNCaP prostate 
cancer cells. The level of IP-10 induction was significantly higher. in PMA 
treated LNCaP cells. Two tailed t test revealed (P <0.0001) which was 
considered statistically significant. Data were analyzed using Graphpad 
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I-PrEC DU145 PC3 LNCaP 
Figure 8. Qualitative analysis MIG mRNA expression in prostate cancer 
cells. Shown are PCR products run on 2.5 % agarose gel and visualized with 
ethidium staining under UV light. Lane 1 : PZ-HPV-7 Immortalized prostate 
epithelial cells, Lane 2: DU145, Lane 3: PC3 and Lane 4: LNCaP. 
Anti-inflammatory responses in prostate cancer cell lines 
Qualitative PCR was performed to evaluate the level mRNA expression of Th2 
chemokine TARC and its cognate receptor CCR4 in prostate tumor cell lines DU145, 
PC3, and LNCaP. Results indicated CCL17 and its receptor CCR4 were up regulated 
in DU145 and PC3 as compared to LNCaP prostate cancer cells and I-PrEC (Fig. 9). 
Qualitative PCR analysis of mRNA expression also revealed that anti-inflammatory 
cytokines IL-4 and IL-10 mRNA were also expressed in these prostate cancer cells 
(Fig. 10). 
MW I-PrEC DU145 PC3 LNCaP 
^aP - GAPDH 350 bp  - 0 - 
Figure 9. Qualitative analysis of chemokine TARC and cognate receptor 
CCR4 mRNA. Shown is the qualitative analysis of TARC and CCR4 mRNA in 
prostate cancer cells. PCR products were resolved on 2.5% agarose gel stained 
with ethidium bromide and visualized under W light. Lane 1: PZ-HPV-7 
immortalized prostate epithelial cells, Lan 2: DU145, Lane 3: PC3 and Lane 4: 
LNCaP prostate cancer cells. GAPDH used as an internal control. 
I-PrEC DU145 PC3 LNCaP 
IL-10 127 bp 
GAPDH 350 bp 
Figure 10. Qualitative analysis of cytokines IL-4 and IL-10 mRNA 
expression in prostate cancer cells. Shown is the qualitative PCR analysis of 
cytokines IL-4 and IL-10 mRNA. PCR products were resolved on 2.5% agarose 
gel stained with ethidium bromide and visualized under UV light. Lane 1 : PZ- 
HPV-7 immortalized prostate epithelial cells, Lane 2: DU145, Lane 3: PC3 and 
Lane 4: LNCaP prostate tumor cells. GAPDH used as an internal control. 
Differential expression of anti-inflammatory cytokine and chemokine mRNA in 
prostate cancer cells 
Quantitative real time PCR was used to determine differential rnRNA 
expression in prostate cancer cells DU145, PC3 and LNCaP. Results indicated that 
anti-inflammatory chemokine CCL17 and its receptor CCR4, as well as anti- 
inflammatory cytokines IL-4 and IL-10 were up regulated in expressed in the prostate 
cancer cell lines (Fig. 11). The over-expression of anti-inflammatory cytokines and 
chemokines in androgen unresponsive prostate cancer cell lines DU145 and PC3, 
suggest degree of aggressiveness and a possible mechanism to evade host immune 
responses. 
I L-4 IL-10 CCLI 7 CCR4 I 
i 
Cytokines and Chemokines 
Figure 11. Quantitative analysis of anti-inflammatory cytokine and 
chemokine mRNA in prostate cancer cells. Shown are the differential 
expressions of increase fold change mRNA in cytokines IL-4, IL-10 and; 
chemokine CCL17 (TARC), and cognate receptor CCR4, in prostate cancer 
cells, DU145, PC3, and LNCaP compared to PZ-HPV-7 immortalized normal 
prostate epithelial cells (I-PrEC) 
DU145 and PC3 Prostate Cancer Cells Secrete Higher levels of IL-10 
Multiplex ELISA performed to quantitate the levels of IL-4 , IL-10 and TARC 
secreted, revealed that there was a statistically significant increase of IL-10 secretion 
in DU145 and PC3, (P < 0.0001) when compared to LNCaP prostate cancer cells and 
I-PrEC (Fig. 12). However, IL-4 and TARC secretion in prostate cancer cells were 
not significant when compared to I-PrEC. High levels of IL-10 in DU145 and PC3 
may also indicate degree of aggressiveness. 
Cell Lines ! 
Figure 12. IL-10 secretion in prostate cancer cells. IL-10 secretion in 
DU145 and PC3 prostate tumor cells was statistically significant (P <0.001) 
when compared LNCaP prostate cancer cell and I-PrEC cells. Data was 
analyzed by (Graphpad Software, San Diego, CA). Standard error bars 
represent * SEM of triplicate samples. 
T cell Chemokine Expression upon Stimulation by Pulsed Dendritic Cells (DCs) 
Bone marrow derived dendritic cells cultured ex-vivo and pulsed with tumor 
antigens were used to stimulate T cells. Results from qualitative and quantitative 
mRNA of Th 1 pro-inflammatory chemokine, IP- 10 and its receptor CXCR3 (Fig. 13) 
showed that IP-10 and its receptor are expressed in T cells. Figs. 14 and 15 are results 
from quantitative PCR analysis to show the differential expression of chemokine IP- 10 
mRNA and cognate receptor CXCR3 respectively, among the five experimental 
groups shown in columns 2 - 6, compared to nayve or non-stimulated T cells. 
Qualitative PCR analysis revealed that anti-inflammatory chemokine TARC mRNA 
and its cognate receptor CCR4 (Fig. 16) were also expressed in T cells. 
The induction of a robust and pre-dominant pro-inflammatory response was 
not observed in T cells stimulated with DCs pulsed with prostate tumor associated 
antigens. Differences among the five experimental groups, as indicated by 
quantitative mRNA expression of chemokine IP- 10 (Fig. 14) and TARC (Fig. 17), 
were not statistically significant. A similar observation was seen in the quantitative 
mRNA expression of chemokine receptors CXCR3 (Fig. 1.5) and CCR4 (Fig. 18). 
Nevertheless, similar chemokine expression profiles seen in prostate cancer cells and 
T cells, suggest that they may interact zn-vivo in a paracrine manner. 
Beta- Actin 350 bp 
Figure 13. Chemokine IP-10 mRNA and cognate receptor CXCR3 
mRNA expression in mice T cells. Qualitative analysis shows PCR 
products that were resolved on 2.5% agarose gel containing ethidium 
bromide and visualized under UV light. Lane 1: DCs only, Lane 2: DCs w/ 
PC3 TAAs, Lane 3: DC w/ DU145 TAAs; Lane 4 DCs w/ LNCaP TAAs, 
and Lane 5: DCs w/ I-PrEC As. Beta Actin used as an internal control. 
1 2 3 4 5 6 
IP-10 
Figure 14. Differential expression of chemokine IP-10 mRNA in mice 
T cells. Shown is the quantitative analysis of fold change increase in 
chemokine IP- 10 rnRNA in mice T cells stimulated with dendritic cells 
(DCs). Column 1 represents non-stimulated T cells. Columns 2 - 6 
represent T cells stimulated with dendritic cells. *- Represent T cells 
stimulated with DCs pulsed with tumor associated antigens (TAAs). 
Figure 15. Differential expression of chemokine receptor CXCR3 
mRNA in mice T cells. Shown is quantitative analysis of chemokine 
CXCR3 mRNA in T cells stimulated with dendritic cells (DCs). Column 
1 represents non-stimulated T cells. Columns 2 - 6 represent T cells 
stimulated with dendritic cells. *- represents T cells stimulated with DCs 
pulsed with tumor associated antigens (TAAs). 
TARC 153 bp 
Beta- Actin 350 bp 
Figure 16. Qualitative analysis of chemokine TARC and cognate 
receptor CCR4 mRNA in mice T cells. PCR products were resolved on 2.5% 
agarose gel containing ethidium bromide and visualized under UV light. Lane 
1: DCs only; Lane 2: DCs wIPC3 TAAs, Lane 3: DC wIDU145 TAAs, Lane 4: 
DCs w1LNCaP TAAs, and Lane 5: DCs w/I-PrEC As 
1 2 3 4 5 6 
TARC 
Figure 17. Differential expression of chernokine TARC mRNA. 
Shown is the quantitative analysis fold change increase in chemokine 
TARC in T cells stimulated with pulse dendritic cells. Column 1, 
represents non-stimulated T cells. Columns 2 - 6, represent T cells 
stimulated with dendritic cells (DCs). *- represents T cells stimulated 
with DCs pulsed with tumor associated antigens (TAAs). 
Figure 18. Differential expression of chemokine receptor CCR4 
mRNA in mice T cells. Shown quantitative analysis of fold change 
increase in chemokine receptor CCR4 mRNA in T cells stimulated with 
pulse dendritic cells (DCs). Column 1 represents non-stimulated T cells. 
Columns 2 - 6 represent T cells stimulated with dendritic cells. *- 
represents T cells stimulated with DCs pulsed with tumor associated 
antigens (TAAs). 
T lymphocyte Cytokines Expression upon Stimulation by Pulsed Dendritic Cell 
(DCs) 
Results from qualitative and quantitative PCR analysis showed that pro- 
inflammatory cytokine IFN-y mRNA (Figs. 19 and 20). Anti-inflammatory cytokine 
IL- 10 rnRNA expression was also observed (Figs. 2 1 and 22). In line with the 
preceding observations of chemokine profiles in T cells, a more robust pro- 
inflammatory Thl- driven response was not potentiated by TAA-pulsed dendritic 
cells. Nevertheless, quantitative PCR showed that IFN-y mRNA expression was 
significantly up regulated (P< 0.05) in T cells stimulated with dendritic cells compared 
to nai've T cells (Fig. 20). This highlights the important role of antigen presenting 
cells in initiating T cell responses. 
IFN-y 11 7 ( bp) 
Beta -actin 350 bp 
Figure 19. Qualitative analysis of IFN-y cytokine mRNA expression in mice 
T cells. Shown are the PCR products of cytokine IFN-y mRNA in mice T cells 
stimulated with dendritic cells. PCR products were resolved on 2.5% agarose gel 
and visualized with ethidium bromide under UV light. Lane 1 : DC only; Lane 2:  
DC W/ PC3 TAAs; Lane 3: DC w/ DU145 TAAs; and Lane 5:  I-PrEC. 
Figure 20. Differential expression cytokine IFN-y mRNA in mice T 
cells. Shown is quantitative analysis of fold change increase in cytokine 
IFN-y in T cells stimulated with dendritic cells. Column 1 represents non- 
stimulated T cells. Columns 2 - 6 represent T cells stimulated with 
dendritic cells. *- represents T cells stimulated with DCs pulsed with 
tumor-associated antigens (TAAs). 
IL-10 175 bp 
Beta -actin 350 bp 
Figure 21. Cytokine IL-10 mRNA expression in mice T cells. Shown 
is Qualitative analysis of PCR of cytokine IL-10 mRNA in mice T cells 
stimulated with dendritic cells. PCR products were resolved on 2.5% 
agarose gel and visualized with ethidium bromide under UV light. Lane 
1: DC only; Lane 2: DC wl PC3 TAAs, Lane 3: DC w/ DU145 TAAs, 
and Lane 5: I-PrEC 
Figure 22. Differential expression of cytokine IL-10 mRNA in mice T 
cells. Shown is the quantitative analysis of fold change increase in cytokine 
IL-10 mRNA in T cells stimulated with pulse dendritic cells. Column 1 
represents non-stimulated T cells. Columns 2 - 6 represent T cells 
stimulated with dendritic cells. *- represent T cells stimulated with DCs 
pulsed with tumor-associated antigens (TAAs). 
CHAPTER 5 
DISCUSSION 
Cytokines, chemokines, and chemokine receptors are essential immune 
effector molecules that play important regulatory roles in immune responses (Grutz, 
2005). Additionally, chemokine and chemokine receptor interactions mediate the 
trafficking and migration of immune cells and non-immune cells including cancers 
(Tanaka et al., 2005). The hypothesis that prostate cancer cell lines differentially 
expressed anti-inflammatory and pro-inflammatory cytokines and chemokines was 
supported by our findings. We demonstrated that the androgen unresponsive prostate 
cancer cell lines DU145 and PC3 expressed anti-inflammatory cytokines IL-4 and IL- 
10, the anti-inflammatory chemokine TARC and chemokine cognate receptor CCR4 
compared to androgen responsive LNCaP prostate cancer cells. Comparative protein 
analysis revealed that pro-inflammatory cytokine IFN-y and the pro-inflammatory 
chemokine IP-10 were significantly down regulated in prostate cancer cells DU145, 
PC3, and LNCaP compared to the immortalized normal prostate epithelial cell line, 
PZ-HPV-7 used in this study. 
Implications of Th2 driven anti-inflammatory cytokine and chemokine 
production in prostate cancer cells 
The roles of anti-inflammatory cytokines and chemokines in immunity and 
cancer progression have been well documented (Sharrna, et al., 1999; Grutz, 2005; 
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Moore et al., 1999). The up regulation of the Th2-driven anti-inflammatory cytokine 
IL-10 suggests a possible mechanism for prostate cancer to evade host immune 
responses. This suggestion is plausible, because high levels of IL- 10 have been 
reported in patients with melanoma, ovarian and colon cancers (Elkord, 2007). 
Moreover, increased serum levels of IL- 10 have been observed in patients with 
breast cancer compared to healthy women (Chavey et al., 2007). Sharma et al., 1999 
reported that IL- 10 had the ability to inhibit a wide array of pro-inflammatory effector 
molecules and also, that elevated levels may negatively modulate antigen presentation 
thus enhancing the evasiveness of tumors. Indeed, Sharma et al., 1999 demonstrated 
that readily induced and augmented levels of IL-10 were produced by T lymphocytes 
in IL-10 transgenic mice. The group also demonstrated that Lewis lung carcinoma 
cells were able to potently induced T lymphocyte IL-10 production in- vitro and had 
a more aggressive growth potential in IL-10 transgenic mice compared to control 
littermates. In  -vivo IL-10 is also known to play a vital role in the induction of 
C D ~ + C D ~ . ~ +  C C R ~ + T  regulatory cells (Ghiringhelli et al., 2005). T regulatory cells 
are important immune regulators because of the suppressive effects on the immune 
system. They exert their suppressive effects by secreting in an autocrine manner of 
IL-10 and TGF-P (Miller et al., 2006). Miller at al., 2006 also reported that significant 
levels of T regulatory cells were detected human cancer specimens. Ghiringhelli et 
al., 2005 also reported similar observations in rodent models of cancer. The 
importance of immunosuppressive effects of IL-10 is further exemplified by the 
impact that they have on antigen presentation. Antigen presenting cells such as 
dendritic cells (DCs) are potent antigen presenting cells (Igietseme et al., 2000) and 
are impacted negatively by IL- 10 (Mcbride et al., 2002). In one study, IL- 10 treated 
dendritic cells were capable of inducing anergy in melanoma specific C D ~ '  T cells 
(Gerlini et al., 2004). Sharma et al., 1999 reported that APCs from IL-10 transgenic 
mice had significantly suppressed capacity to up regulate MHC, cytolytic responses 
and IL-12 production that are necessary for activating T cells. Miller et al., 2006 
further demonstrated by using 5-bromo-2'-deoxyridine (BrdU) incorporation assay, 
they were able to show that T cell function can be compromised by prostate cancer 
tissue supernatants because they significantly inhibited T cells proliferation. The up 
regulation of immunosuppressive cytokine such as IL- 10 therefore may have 
important implications in cancer immunotherapy. 
Although high levels of the anti-inflammatory cytokine IL-4 have been 
reported in many advanced tumors including prostate cancer tissues (Concetta et al., 
2004), we did not detect high levels of IL-4 the prostate cancer cell lines used in this 
study. 
We also demonstrated that unlike anti-inflammatory responses, pro- 
inflammatory responses such as cytokine IFN-y and chemokine IP- 10 were 
significantly down regulated. These effector molecules are important in mediating 
anti-tumor responses. The role of IFN-y as an anti-tumor mediator is supported by a 
study done by Frederick et al., 2001 to show that IFN-y inhibited the growth of PC3 
and DU145 prostate cancer cell lines in a dose dependent manner. Additionally, IFN- 
y has been shown to have direct cytotoxic effects on squamous cell carcinoma of head 
and neck cancers in-vitro and can enhance cell-mediated responses to head and neck 
cancers (Quinn, 1998). It has also been demonstrated that mice that lack IFN-y or 
IFN-y receptors developed tumors more rapidly upon exposure to carcinogens (Elkord, 
2007). 
Pro-inflammatory chemokine IP-10 down regulation in prostate cancer cells 
suggests that prostate cancer cells are likely to promote angiogenesis, by negatively 
modulating IP-10 production. This observation is in line with Sato et al., 2007 who 
reported that the levels of IP-10 decreased with the advancement of uterine cervical 
cancers where as, the levels of angiogenic chemokine VEGF were high and the 
prognosis of the cancer with low IP-10 expression was poor. Moreover, they would 
be less likely to recruit T cytotoxic cells bearing the cognate receptor CXCR3 which 
are the main effector cells that are involved in the targeted killing of cancer cells 
(Nouri-shirazi et al,., 2000; Arenberg et al., 1996). This correlates with Mullins et al., 
2004, who reported that the expression of CXCR3, the receptor for IP-10 by activated 
T cells, correlated with greater survival of patients with stage I11 melanoma cancer. A 
similar mechanism of IP- 10 regulation presumably, will destroy prostate tumors and 
reduce their progression. In- vivo, IP- 10 is known to preferentially target natural killer 
cells and will activate cells of the Thl phenotype through the CXCR3 receptor 
(Nagaoka et al., 2002). Sato et al., 2007 concluded that IP-10 could be used as a 
prognostic biomarker for disease progression. 
An interesting finding was that, Phorbol- 12- Myristate- 13 Acetate (PMA), a 
potent mitogen that activates the PKC signal transduction pathway (Gonzalez, G et al., 
2005), caused significant up regulation of interferon inducible protein IP-10 in 
androgen responsive LNCaP prostate cancer cells. The over expression of IP-10 has 
been shown to have anti-proliferative effects and decreased PSA production in LNCaP 
prostate cancer cells (Nagpal et al., 2006). Gonzalez, et al., 2005, showed that PMA 
mediated PKC pathway, specifically the PKC isozyme PKC 6, induced apoptosis in 
LNCaP prostate cancer cells. There is a strong possibility, that PMA mediated 
apoptosis in LNCaP is via induction of IP- 10. IP- 10 induction has also been reported 
to up regulate transcription factor and tumor suppressor gene p53, known to be 
important in cell cycle arrest and apoptosis (Zhang et al., 2005). The effects of PMA 
on the up regulation of cytokines IFN-)I, IL-4 and IL- 10 as well as chemokine were 
not significant. From all indications, IP-10 could be used as a potential therapeutic to 
interfere with prostate cancer progression. 
Through gene expression studies, we were also able to demonstrate that Th2 
anti-inflammatory chemokine TARC and cognate receptor CCR4 were up regulated in 
androgen unresponsive prostate cancer cell lines DU145 and PC3. This autocrine 
regulation, presumably indicates degree of aggressiveness because the aggressiveness 
of cancers is often characterized by their resistance or unresponsiveness to androgen 
ablation therapy (Elkord, 2007). Miller et al., 2006 showed that ELISA analysis of 
culture supernatants of LNCaP cells, secreted low levels of chemokine CCL22 or 
MDC (0.12 + 0.05 nglml) which share the same receptor CCR4 as TARC (Charo et 
al., 2006). Higher levels were detected in malignant prostate tissue. 
Dendritic Cells as Immunotherapeutic Adjuvants 
The in-vivo studies conducted to test the hypothesis that prostate tumor antigen 
pulsed dendritic cells would influence the profile of cytokines, chemokines and their 
receptors, revealed that dendritic cells were able to activate T cells, but we did not 
observe a pre-dominant pro-inflammatory response indicative of the upregulation of 
cytokine IFN--y and chemokine IP- 10, as well as the chemokine receptor CXCR3 
which usually indicates presence of activated T killer cells (Tannenbaum et al., 1998). 
Indeed our gene expression studies detected elevated levels of anti-inflammatory 
cytokine IL-10 mRNA and anti-inflammatory chemokine TARC mRNA, as well as its 
cognate receptor CCR4. These observations did not support the hypothesis that TAAs 
pulsed dendritic cells would potentiate a more robust pro-inflammatory response. 
Limitations to this particular study could be the antigenic dosage used, the efficiency 
of antigenic uptake by dendritic cells and the presence of endogenous immune 
suppressive factors. Indeed, the mixed Thl-pro-inflammatory and Th2- anti- 
inflammatory cytokine and chemokine profiles could be attributed to the recruitment 
of the C C R ~ + T ~ ~ ~  subset of T cells. Since mature dendritic cells are known to express 
the TARC (Charo et al., 2006), it is possible that they may have influenced the 
recruitment of this distinct subset of T cells. Troy, A et al., 1998, demonstrated that 
dendritic cells that have been identified in prostate tissue could induce the formation 
of T regulatory cells. Nevertheless, the similar cytokine and chemokine profiles seen 
in prostate cancer cells and T cells, suggests that they can interact in-vivo in a 
paracrine manner. 
Taken together, the immune response to cancer can often be compromised by 
the immune suppressive effects of anti-inflammatory cytokines and chemokines.. 
Additionally, the inadequacy of dendritic cells due to the immune suppressive effects 
of cancer has been well documented to be one of the main reasons for ineffective anti- 
tumor responses (Sharma et al., 1999). 
CHAPTER 6 
CONCLUSION 
Prostate cancer cells DU145, PC3 and LNCaP were shown to differentially 
express anti-inflammatory and pro-inflammatory cytokines and chemokines. The 
down regulation of key mediators involved in anti-tumor responses, IFN-)I and IP-10 
in these prostate cancer cell lines and concomitant increase in IL- 10 and TARC 
suggest that prostate cancer cells take advantage of the of anti-inflammatory responses 
that are often immune suppressive, to negatively modulate functions that are necessary 
for the killing cancer cells. The similar cytokine and chemokine expression profiles in 
prostate cancer cells and T cells, gives us reason to believe that there are paracrine 
interactions involved in-vivo in immunity against prostate cancer. 
Ongoing studies demonstrate that dendritic cells are a potential vehicle to 
deliver specific target antigens to T cells, specifically those involved in anti-tumor 
responses. Dendritic cell biology is also important in the context of cancer 
immunology since its functions are known to be severely compromised by IL- 10. The 
influence of paracrine and autocrine interactions between T cells, dendritic cells and 
prostate cancer cell lines and their effects on migration and survival of prostate 
cancers, should be further investigated. Cytokine and chemokine profiles could be 
used as prognostic markers for prostate cancer progression. 
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